3647 results for «604»
3647 results
An intrepid solution for transfemoral treatment of mitral regurgitation
21 Nov 2023 – From PCR London Valves 2023
In this session, get insights into the APOLLO EU trial and its current progress, obtain a comprehensive understanding of the latest data from the Early Feasibility TF trial, and discern which patients stand to benefit the most from this treatment.
TAVI - Alternative access - Part 1
19 Nov 2023 – From PCR London Valves 2023
Learn more about the evolving landscape of TAVI techniques and access options with this session: experience the first-hand application of JenaValve Trilogy via transaxillary access in treating aortic regurgitation, delve into the challenges and solutions of transcaval TAVI in a patient with right iliac vein occlusion,...
TAVI in bicuspid anatomy - Part 1
19 Nov 2023 – From PCR London Valves 2023
Delve into the complexities of TAVI within bicuspid anatomy through this selection of cases: encounter a challenging scenario with a bicuspid aortic valve, where the ejection fraction is -14%, coupled with left ventricle thrombus and an aortic valve calcium score reaching 11,000, learn more about the...
Tricuspid TEER - Part 1
19 Nov 2023 – From PCR London Valves 2023
Gain insights into Tricuspid Transcatheter Edge-to-Edge Repair (TEER) with this session: explore the congestion patterns observed in severe tricuspid regurgitation and gain a deeper understanding of transcatheter treatment modalities, delve into the baseline characteristics of the Tri.Fr randomized trial on treating tricuspid regurgitation, witness the application...
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.
Author
Author
